腹主动脉瘤修复术后慢性肾脏病对死亡率的预测强于查尔森共病指数
单中心回顾性队列研究纳入2014至2024年接受腹主动脉瘤修复术的患者,经倾向评分匹配后比较无慢性肾脏病组与慢性肾脏病组各106例;慢性肾脏病组死亡率显著更高(无慢性肾脏病17.9% vs 慢性肾脏病32.1%,P=0.017),5期慢性肾脏病与死亡率的关联强于查尔森共病指数。
要点
- 匹配后慢性肾脏病组死亡率17.9% vs 32.1%(P=0.017),慢性肾脏病组更高。
- 5期慢性肾脏病与死亡率的OR为9.33(95%CI 1.26-97.09,P=0.04)。
- 作者认为降低中期死亡率的策略可包括加强术前优化和个体化诊疗。
核心结论
- 作者认为较高的查尔森共病指数和慢性肾脏病分期是腹主动脉瘤修复术后死亡率升高的危险因素。
- 亚组分析显示5期慢性肾脏病与死亡率的关联强于查尔森共病指数。
研究设计与样本
- 单中心回顾性队列研究,纳入2014年至2024年接受腹主动脉瘤修复术的患者。
- 经倾向评分匹配(基于年龄、性别、高血压、糖尿病、吸烟状态和冠状动脉疾病)后共212例,无慢性肾脏病组(GFR≥60 mL/min)106例,慢性肾脏病组(GFR<60 mL/min)106例。
主要发现
- 两组年龄(无慢性肾脏病75.29±8.17岁 vs 慢性肾脏病75.94±8.80岁,P=0.576)、性别比例(P=0.846)和平均家庭收入(无慢性肾脏病99199.08±37846.82美元 vs 慢性肾脏病91333.38±32128美元,P=0.091)相似。
- 慢性肾脏病组查尔森共病指数评分显著更高(无慢性肾脏病4.99±1.96 vs 慢性肾脏病6.11±2.26,P<0.001)。
- 30天并发症(无慢性肾脏病5.7% vs 慢性肾脏病7.5%,P=0.580)和主动脉相关再干预率(无慢性肾脏病13.2% vs 慢性肾脏病12.3%,P=0.837)两组相当。
- 慢性肾脏病组死亡率显著更高(无慢性肾脏病17.9% vs 慢性肾脏病32.1%,P=0.017)。
- 逻辑回归分析显示5期慢性肾脏病(OR 9.33,95%CI 1.26-97.09,P=0.04)、慢性肾脏病(OR 2.16,95%CI 1.15-4.17,P=0.018)和查尔森共病指数评分(OR 1.42,95%CI 1.26-1.67,P<0.001)与死亡率显著相关。
关键数值与推荐
- 慢性肾脏病定义为GFR<60 mL/min,无慢性肾脏病定义为GFR≥60 mL/min。
- 5期慢性肾脏病与死亡率的OR为9.33(95%CI 1.26-97.09,P=0.04)。
- 慢性肾脏病与死亡率的OR为2.16(95%CI 1.15-4.17,P=0.018)。
- 查尔森共病指数评分与死亡率的OR为1.42(95%CI 1.26-1.67,P<0.001)。
临床怎么用
- 作者认为降低中期死亡率的策略可包括加强术前优化和个体化诊疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients undergoing abdominal aortic aneurysm (AAA) repair face elevated mortality risk associated with advanced age and comorbidities, including chronic kidney disease (CKD). CKD alone demonstrates an increased risk for mortality in patients. Our cohort study aimed to identify whether CKD and/or comorbid burden using the Charlson Comorbidity Index (CCI) are potential contributors toward negative outcomes in patients who underwent AAA repair. METHODS: We conducted a single-center retrospective cohort study on patients undergoing AAA repair between 2014 and 2024. The primary outcome is comorbidity burden (measured with CCI) and disease-specific burden (CKD measured by glomerular filtration rate (GFR)), as contributors to increased risk for mortality. Secondary outcomes included 30-day and mid-term complications and reinterventions after AAA repair. Propensity score matching was also conducted based on age, sex, hypertension, diabetes, smoking status, and coronary artery disease to assess for CKD and CCI burden. RESULTS: A total of 212 matched patients underwent AAA repair, with 106 patients in the no CKD (GFR ≥60 mL/min) group and 106 in the CKD (GFR <60 mL/min) group. Sociodemographic variables, including age (no CKD: 75.29 ± 8.17 vs. CKD: 75.94 ± 8.80; P = 0.576), sex proportions (P = 0.846), and mean household income (no CKD: $99,199.08 ± 37,846.82 vs. CKD: $91,333.38 ± 32,128; P = 0.091), were similar between groups. Patients with CKD had significantly higher CCI scores (no CKD: 4.99 ± 1.96 vs. CKD: 6.11 ± 2.26; P < 0.001). Thirty-day complications (no CKD: 5.7% vs. CKD: 7.5%; P = 0.580) and aortic-related reintervention rates (no CKD: 13.2% vs. CKD: 12.3%; P = 0.837) were comparable between groups. Mortality was significantly higher in the CKD group (no CKD: 17.9% vs. CKD: 32.1%; P = 0.017). Logistic regression analysis demonstrated that stage 5 CKD (odds ratio (OR): 9.33, 95% confidence interval (CI): 1.26-97.09; P = 0.04), CKD (OR: 2.16 95% CI: 1.15-4.17; P = 0.018), and CCI score (OR: 1.42, 95% CI: 1.26-1.67; P < 0.001) are significantly associated with mortality. CONCLUSION: Higher CCI and CKD stage are risk factors for a higher mortality rate in patients who underwent AAA repair. Subgroup analysis between CKD stages demonstrated that stage 5 has a stronger association with mortality than CCI. Strategies to decrease mid-term mortality rates might include enhanced preoperative optimization and individualized approach to care.
引用
- Arroyo HM, Farres H, Medina YC, et al. Chronic Kidney Disease is a Stronger Predictor for Mortality than Charlson Comorbidity Index after Abdominal Aortic Aneurysm Repair. Ann Vasc Surg. 2025. PMID: 40233895. doi:10.1016/j.avsg.2025.03.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。